Predicting Response to Capecitabine in Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Identifying genes that increase a person's susceptibility to side effects caused
by capecitabine may help doctors plan better treatment.
PURPOSE: This clinical trial is studying blood samples in predicting response to capecitabine
in women with metastatic breast cancer.